drugset / Trial / NCT01429688

Pharmacokinetic / Pharmacodynamic (PK/PD) Study of Multiple Doses of DP-R202 in Healthy Volunteers

NCT01429688

Phase 1 Completed 36 enrolled Alvogen Korea
RandomizedCrossoverOpen-label

Summary

The purpose of this study is compare the safety and pharmacokinetic characteristics of DP-R202 (Sarpogrelate HCl 100mg, qd) with those of Anplag (Sarpogrelate HCl 100mg, tid) after multiple oral administration in healthy male volunteers.

Timeline

Start
2011-07
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Sarpogrelate Small molecule 100 mg Oral
Subject Sarpogrelate Small molecule 300 mg Oral

Indications

No indication recorded.